WAVE Life Sciences (NASDAQ:WVE) Trading Down 10.6% Following Insider Selling

WAVE Life Sciences Ltd. (NASDAQ:WVE) traded down 10.6% on Friday after an insider sold shares in the company. The stock traded as low as $13.68 and last traded at $13.7350. 1,098,302 shares were traded during mid-day trading, a decline of 70% from the average session volume of 3,627,507 shares. The stock had previously closed at $15.36.

Specifically, insider Chris Francis sold 33,194 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the transaction, the insider owned 61,867 shares in the company, valued at $931,098.35. This represents a 34.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Wall Street Analysts Forecast Growth

WVE has been the subject of a number of research analyst reports. Raymond James Financial reaffirmed an “outperform” rating and issued a $21.00 target price on shares of WAVE Life Sciences in a research note on Monday, December 8th. Leerink Partners restated an “outperform” rating on shares of WAVE Life Sciences in a research report on Monday, December 8th. Bank of America began coverage on WAVE Life Sciences in a report on Thursday, February 5th. They set a “buy” rating and a $38.00 price objective on the stock. Wall Street Zen cut WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Finally, Wells Fargo & Company cut their price target on WAVE Life Sciences from $29.00 to $27.00 and set an “overweight” rating on the stock in a research note on Thursday, February 12th. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

WAVE Life Sciences News Roundup

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: INHBE obesity program progressing — Wave is advancing WVE‑007 (INHBE GalNAc‑siRNA) and is positioning it as a once‑ or twice‑yearly obesity treatment; early data show fat loss at three months similar to GLP‑1s while preserving muscle, which if confirmed could be a high‑value, low‑frequency dosing differentiator. Wave Life Sciences targets once or twice yearly obesity treatment as INHBE program advances
• Positive Sentiment: On track for near‑term clinical readout — Company press release reiterates INLIGHT data update expected in 1Q 2026 and highlights durable fat‑loss signals and dose‑response expectations for WVE‑007, providing a clear upcoming catalyst. Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Q4 call and transcript show mixed messaging — Management walked through a revenue beat but flagged pressures and gave operational context on the pipeline; the call transcript and highlight pieces provide detail for modeling near‑term revenue and R&D cadence. Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics — WVE reported Q4 EPS of ($0.30), missing consensus by $0.02, though revenue of $17.25M topped expectations; the company still shows large negative margins and negative ROE, underscoring continued cash burn and dilution risk. Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Insider sale by a senior executive — Chris Francis sold 33,194 shares (~$15.05 avg), cutting his ownership nearly 35%; while insider sales can be for personal reasons, markets often interpret sizable reductions by executives as a near‑term negative signal. Chris Francis insider sale

WAVE Life Sciences Stock Performance

The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -11.42 and a beta of -1.78. The company has a 50-day moving average price of $14.45 and a 200-day moving average price of $10.81.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.02). The firm had revenue of $17.25 million for the quarter. WAVE Life Sciences had a negative return on equity of 140.75% and a negative net margin of 478.35%. As a group, sell-side analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On WAVE Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. CWM LLC increased its position in shares of WAVE Life Sciences by 6,729.0% in the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock valued at $36,000 after buying an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in WAVE Life Sciences by 645.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after acquiring an additional 1,942 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of WAVE Life Sciences in the fourth quarter worth about $82,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of WAVE Life Sciences by 32.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company’s stock worth $138,000 after acquiring an additional 1,972 shares in the last quarter. Finally, Bessemer Group Inc. raised its position in shares of WAVE Life Sciences by 1,156.3% during the third quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock worth $72,000 after purchasing an additional 9,135 shares during the period. 89.73% of the stock is owned by institutional investors.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.